TENX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (NASDAQ: TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

TENX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (NASDAQ:TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

NEW YORK CITY, NY / ACCESS Newswire / October 27, 2026 / If you purchased or acquired securities in Tenax between November 13, 2023 and August 7, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ:TENX) and reminds investors of the December 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

The truth began to emerge on August 10, 2026, when Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. This press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock price fell approximately $12.06 per share, or 89.77%, to close at approximately $1.38 per share on August 10, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Tenax's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Tenax class action, go to www.faruqilaw.com/TENX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Frequently Asked Questions (FAQ) for Investors Regarding the Tenax Therapeutics Securities Class Action Lawsuit:

What is the Tenax securities fraud lawsuit about?

The lawsuit alleges Tenax Therapeutics misled investors about TNX-103's efficacy and clinical, regulatory, and commercial prospects before the drug failed key endpoints in its Phase 3 LEVEL trial.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired Tenax Therapeutics (NASDAQ:TENX) securities between November 13, 2023 and August 7, 2026 may be eligible if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by December 28, 2026. Investors may participate without serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Tenax Therapeutics securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE: Faruqi & Faruqi, LLP